NCT00609999 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Ph I Dasatinib + Erlotinib in Recurrent MG


Sponsors: Duke University Bristol-Myers Squibb Genentech	Phases: Phase I
Indications	Acronym:
Glioblastoma Gliosarcoma
Age Groups: Adult Senior	Gender: Both
Names: Drug: Erlotinib and Dasatinib	Enrollment: 48

Additional information about NCT00609999.